Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile
Status: Archived
Northwestern University
mi
from
Chicago, IL
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile
Status: Archived
The Ruth M. Rothstein CORE Center
mi
from
Chicago, IL
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile
Status: Archived
Updated: 1/1/1970
The Ruth M. Rothstein CORE Center
mi
from
Chicago, IL
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile
Status: Archived
University of Nebrasaka Medical Center
mi
from
Omaha, NE
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile
Status: Archived
Updated: 1/1/1970
University of Nebrasaka Medical Center
mi
from
Omaha, NE
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
A Pilot, Open-Label Study of Adjunctive Therapy With Lovaza® in Hypertriglyceridemic, HIV-Infected Subjects Who Switched Protease Inhibitor to Once-Daily Lexiva® 1400mg Plus Norvir® 100mg Plus Optimized Background
Status: Archived
Franco Felizarta, MD
mi
from
Bakersfield, CA
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
A Pilot, Open-Label Study of Adjunctive Therapy With Lovaza® in Hypertriglyceridemic, HIV-Infected Subjects Who Switched Protease Inhibitor to Once-Daily Lexiva® 1400mg Plus Norvir® 100mg Plus Optimized Background
Status: Archived
Updated: 1/1/1970
Franco Felizarta, MD
mi
from
Bakersfield, CA
Clinical Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Patients With Primary Immunodeficiency Diseases
Clinical Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam)in Patients With Primary Immunodeficiency Diseases
Status: Archived
Dr. Alan Knutsen
mi
from
St. Louis, MO
Clinical Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Patients With Primary Immunodeficiency Diseases
Clinical Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam)in Patients With Primary Immunodeficiency Diseases
Status: Archived
Updated: 1/1/1970
Dr. Alan Knutsen
mi
from
St. Louis, MO
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma
Status: Archived
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma
Status: Archived
Updated: 1/1/1970
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma
Status: Archived
University of Maryland, Baltimore
mi
from
Baltimore, MD
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma
Status: Archived
Updated: 1/1/1970
University of Maryland, Baltimore
mi
from
Baltimore, MD
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma
Status: Archived
Stony Brook University Hospital and Medical Center
mi
from
Stony Brook, NY
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma
Status: Archived
Updated: 1/1/1970
Stony Brook University Hospital and Medical Center
mi
from
Stony Brook, NY
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma
Status: Archived
St. Christopher's Hospital for Children/ Drexel University College of Medicine
mi
from
Philadelphia, PA
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma
Status: Archived
Updated: 1/1/1970
St. Christopher's Hospital for Children/ Drexel University College of Medicine
mi
from
Philadelphia, PA
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma
Status: Archived
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma
Status: Archived
Updated: 1/1/1970
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
A Pilot Study to Evaluate the Effectiveness of a Tenofovir Raltegravir Switch in Resolving Tenofovir Induced Proteinuria in HIV Infected Individuals With Undetectable HIV Viral Loads
Status: Archived
Living Hope Foundation
mi
from
Long Beach, CA
Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
A Pilot Study to Evaluate the Effectiveness of a Tenofovir Raltegravir Switch in Resolving Tenofovir Induced Proteinuria in HIV Infected Individuals With Undetectable HIV Viral Loads
Status: Archived
Updated: 1/1/1970
Living Hope Foundation
mi
from
Long Beach, CA
Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
A Pilot Study to Evaluate the Effectiveness of a Tenofovir Raltegravir Switch in Resolving Tenofovir Induced Proteinuria in HIV Infected Individuals With Undetectable HIV Viral Loads
Status: Archived
Metropolis Medical Group
mi
from
San Francisco, CA
Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
A Pilot Study to Evaluate the Effectiveness of a Tenofovir Raltegravir Switch in Resolving Tenofovir Induced Proteinuria in HIV Infected Individuals With Undetectable HIV Viral Loads
Status: Archived
Updated: 1/1/1970
Metropolis Medical Group
mi
from
San Francisco, CA
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Adherence Intervention for People With Low-literacy
HIV Treatment Adherence Intervention for People With Poor Literacy Skills
Status: Archived
Southeast HIV/AIDS Research and Evaluation Project
mi
from
Atlanta, GA
Adherence Intervention for People With Low-literacy
HIV Treatment Adherence Intervention for People With Poor Literacy Skills
Status: Archived
Updated: 1/1/1970
Southeast HIV/AIDS Research and Evaluation Project
mi
from
Atlanta, GA
Study of PENNVAXâ„¢-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants
A Phase I, Open Label Study to Evaluate the Safety, Tolerability and Immunogenicity of PENNVAXâ„¢-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of PENNVAXâ„¢-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants
A Phase I, Open Label Study to Evaluate the Safety, Tolerability and Immunogenicity of PENNVAXâ„¢-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Sustiva Levels With Use of a Gel Capsule
Effect of Encapsulation Upon Efavirenz Pharmacokinetics
Status: Archived
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Sustiva Levels With Use of a Gel Capsule
Effect of Encapsulation Upon Efavirenz Pharmacokinetics
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Vitamin D Dose Finding Study
Safe and Effective Vitamin D Supplementation in HIV
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Vitamin D Dose Finding Study
Safe and Effective Vitamin D Supplementation in HIV
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I Study)
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I Study)
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Rhode Island Hospital
mi
from
Providence, RI
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
mi
from
Providence, RI
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
GSK Investigational Site
mi
from
Glendale, AZ
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Glendale, AZ
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
GSK Investigational Site
mi
from
Aurora, CO
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Aurora, CO
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
GSK Investigational Site
mi
from
Washington,
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Washington,
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
GSK Investigational Site
mi
from
Roswell, GA
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Roswell, GA
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
McFarland Clinic, PC
mi
from
Ames, IA
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
McFarland Clinic, PC
mi
from
Ames, IA
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
GSK Investigational Site
mi
from
Grand Rapids, MI
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Grand Rapids, MI
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
GSK Investigational Site
mi
from
Cherry Hill, NJ
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Cherry Hill, NJ
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
GSK Investigational Site
mi
from
Knoxville, TN
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Knoxville, TN
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
GSK Investigational Site
mi
from
Kennewick, WA
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Kennewick, WA
DCVax Plus Poly ICLC in Healthy Volunteers
A Randomized, Placebo-controlled, Dose-escalating, Double-blinded Phase I Study to Evaluate the Safety and Immunogenicity of Anti-DEC-205 Monoclonal Antibody (Mab) Targeted HIV Gag p24 Vaccine (DCVax-001) With Poly ICLC (Hiltonol) as Adjuvant in HIV-uninfected Healthy Volunteers
Status: Archived
The Rockefeller University Hospital
mi
from
New York, NY
DCVax Plus Poly ICLC in Healthy Volunteers
A Randomized, Placebo-controlled, Dose-escalating, Double-blinded Phase I Study to Evaluate the Safety and Immunogenicity of Anti-DEC-205 Monoclonal Antibody (Mab) Targeted HIV Gag p24 Vaccine (DCVax-001) With Poly ICLC (Hiltonol) as Adjuvant in HIV-uninfected Healthy Volunteers
Status: Archived
Updated: 1/1/1970
The Rockefeller University Hospital
mi
from
New York, NY
Reducing Health Problems Associated With Injection Drug Use
Reduction of Medical Complications Associated With Injection Drug Use
Status: Archived
Project Safe, University of Colorado
mi
from
Denver, CO
Reducing Health Problems Associated With Injection Drug Use
Reduction of Medical Complications Associated With Injection Drug Use
Status: Archived
Updated: 1/1/1970
Project Safe, University of Colorado
mi
from
Denver, CO
Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
Phase I/IIA Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
Status: Archived
Clinilabs Inc.
mi
from
New York, NY
Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
Phase I/IIA Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
Status: Archived
Updated: 1/1/1970
Clinilabs Inc.
mi
from
New York, NY
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Arizona Research Center
mi
from
Phoenix, AZ
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
Arizona Research Center
mi
from
Phoenix, AZ
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Southwest Center for HIV/AIDS
mi
from
Phoenix, AZ
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
Southwest Center for HIV/AIDS
mi
from
Phoenix, AZ
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Providence Clinical Research
mi
from
San Fernando Valley, CA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
Providence Clinical Research
mi
from
San Fernando Valley, CA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Anthony Mills MD Inc
mi
from
Los Angeles, CA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
Anthony Mills MD Inc
mi
from
Los Angeles, CA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
AIDS Research Alliance of America
mi
from
Los Angeles, CA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
AIDS Research Alliance of America
mi
from
Los Angeles, CA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Desert Medical Group, Inc. dba Desert Oasis Healthcare Medical Group
mi
from
Palm Springs, CA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
Desert Medical Group, Inc. dba Desert Oasis Healthcare Medical Group
mi
from
Palm Springs, CA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Stanford Clinical Research Center
mi
from
Stanford, CA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
Stanford Clinical Research Center
mi
from
Stanford, CA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Neuroscience Consultants, Limited Liability Corporation
mi
from
Aventura, FL
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
Neuroscience Consultants, Limited Liability Corporation
mi
from
Aventura, FL
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
South Florida Medical Research
mi
from
Miami, FL
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
South Florida Medical Research
mi
from
Miami, FL
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
The Kinder Medical Group
mi
from
Miami, FL
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
The Kinder Medical Group
mi
from
Miami, FL
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Wohlfeiler, Piperato and Associates, LLC
mi
from
Miami Beach, FL
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
Wohlfeiler, Piperato and Associates, LLC
mi
from
Miami Beach, FL
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
AIDS Research Consortium of Atlanta
mi
from
Atlanta, GA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
AIDS Research Consortium of Atlanta
mi
from
Atlanta, GA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Neurology Specialists of Decatur Research Center
mi
from
Decatur, GA
Pregabalin Trial In HIV Neuropathic Pain
An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)
Status: Archived
Updated: 1/1/1970
Neurology Specialists of Decatur Research Center
mi
from
Decatur, GA